Hospital
HMH Hospitals Corporation
HMH Hospitals Corporation was paid $79.26M by Medicaid between Apr 2018 and Dec 2024, across 367 billing codes. Its largest line is 99283, emergency room visit (moderate) — 19% of everything it billed.
33Billing provider infoHMH HOSPITALS CORPORATION
NORTH BERGEN, NJ 07047
NORTH BERGEN, NJ 07047
33aNPI1730692344assigned 11/06/2017
33bProvider typeGeneral Acute Care Hospital
28Total paid$79.26M
24GClaims1,568,459
24DCodes billed367
24AFirst – last monthApr 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in New Jersey
Rank by total paid#22 of 93
Median peer was paid$30.60M
This provider vs. median2.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 91,527 | $5.68M | |
| 2019 | 209,743 | $11.69M | |
| 2020 | 140,398 | $7.07M | |
| 2021 | 235,244 | $11.20M | |
| 2022 | 305,595 | $14.70M | |
| 2023 | 322,483 | $16.03M | |
| 2024incomplete | 263,469 | $12.91M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 19% | 50,389 | 45,640 | $15.19M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 19% | 41,640 | 37,727 | $14.67M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 5.6% | 42,053 | 9,743 | $4.42M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.1% | 11,349 | 10,617 | $3.22M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.5% | 12,723 | 12,186 | $2.75M |
| G0378 | Hospital observation service, per hour | 3.2% | 7,614 | 6,324 | $2.51M |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 2.9% | 2,077 | 2,016 | $2.31M |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 2.6% | 34,267 | 10,075 | $2.04M |
| 90832 | Psychotherapy session, about 30 minutesPsychotherapy, 30 minutes with patient | 2.4% | 16,847 | 10,091 | $1.87M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.8% | 1,945 | 1,877 | $1.46M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.5% | 7,936 | 7,437 | $1.18M |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 1.3% | 1,778 | 1,663 | $1.06M |
355 more codes
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.3% | 22,755 | $1.04M |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 1.2% | 40,508 | $987K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.2% | 3,327 | $968K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 1.2% | 1,445 | $965K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.2% | 58,286 | $935K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 10,697 | $759K |
| 95782 | <1% | 562 | $736K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 18,246 | $713K |
| OP370 | <1% | 11,082 | $688K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 22,156 | $621K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 5,385 | $582K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 13,546 | $554K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 6,042 | $492K |
| OP710 | <1% | 7,105 | $488K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 17,239 | $467K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 3,763 | $426K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 15,259 | $426K |
| 95811 | <1% | 431 | $414K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 16,565 | $389K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 3,514 | $368K |
| 97129 | <1% | 3,674 | $361K | |
| 80053 | Comprehensive metabolic panel | <1% | 60,963 | $361K |
| 90863 | <1% | 2,821 | $350K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 1,754 | $348K |
| 93017 | <1% | 1,404 | $341K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,773 | $338K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 28,073 | $316K |
| 76830 | Ultrasound, transvaginal | <1% | 3,575 | $294K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 4,104 | $288K |
| 71045 | Radiologic examination, chest; single view | <1% | 18,032 | $276K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 3,678 | $274K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 59,971 | $243K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 10,304 | $238K |
| 97162 | <1% | 4,892 | $230K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 4,865 | $220K |
| OP250 | <1% | 98,768 | $204K | |
| 97116 | <1% | 6,277 | $198K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 2,299 | $196K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 4,376 | $191K |
| OP272 | <1% | 11,962 | $191K | |
| 97161 | <1% | 3,403 | $190K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 784 | $190K |
| 59025 | Fetal non-stress test | <1% | 1,566 | $181K |
| 76801 | <1% | 2,244 | $181K | |
| 95806 | <1% | 209 | $174K | |
| 92523 | <1% | 1,450 | $169K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,477 | $168K |
| 97533 | <1% | 4,793 | $161K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 15,411 | $158K |
| S9480 | Intensive outpatient psychiatric services, per diem | <1% | 212 | $151K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,685 | $148K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,357 | $141K |
| 76641 | <1% | 1,311 | $135K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,205 | $135K |
| 93970 | <1% | 922 | $131K | |
| 76770 | <1% | 1,902 | $131K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,100 | $130K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 11,392 | $128K |
| 77066 | Tomosynthesis, mammo | <1% | 1,264 | $120K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,669 | $115K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 3,538 | $114K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 4,071 | $113K |
| 36415 | Collection of venous blood by venipuncture | <1% | 56,897 | $107K |
| 71250 | <1% | 1,335 | $101K | |
| 90837 | Psychotherapy session, about an hour | <1% | 1,455 | $95K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 944 | $94K |
| 76813 | <1% | 870 | $90K | |
| 77080 | <1% | 1,445 | $87K | |
| 73564 | <1% | 3,106 | $85K | |
| 84484 | <1% | 20,154 | $84K | |
| 94060 | <1% | 361 | $83K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 9,782 | $82K |
| 76642 | <1% | 1,313 | $79K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,107 | $77K |
| 83880 | <1% | 8,746 | $73K | |
| 27447 | <1% | 27 | $71K | |
| 97165 | <1% | 1,045 | $69K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 644 | $68K |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 701 | $67K |
| 76536 | <1% | 932 | $65K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 75 | $65K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 5,040 | $65K |
| 73630 | <1% | 3,161 | $64K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 113 | $64K |
| 73030 | <1% | 2,762 | $62K | |
| 0002A | <1% | 2,307 | $58K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 2,204 | $58K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 518 | $57K |
| 70486 | <1% | 785 | $57K | |
| 83735 | <1% | 23,465 | $57K | |
| OP270 | <1% | 6,888 | $55K | |
| 84703 | <1% | 25,183 | $54K | |
| OP258 | <1% | 38,636 | $53K | |
| 0001A | <1% | 2,232 | $53K | |
| 93971 | <1% | 718 | $53K | |
| 96367 | <1% | 2,513 | $52K | |
| 96376 | <1% | 3,001 | $50K | |
| 82948 | <1% | 21,591 | $49K | |
| 83605 | <1% | 11,520 | $49K | |
| 73130 | <1% | 2,466 | $48K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 573 | $47K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 51 | $47K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,964 | $47K |
| C1776 | Joint device (implantable) | <1% | 79 | $46K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,320 | $45K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 13,978 | $44K |
| 73610 | <1% | 2,509 | $44K | |
| 83690 | <1% | 18,382 | $43K | |
| 93976 | <1% | 289 | $42K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 3,853 | $41K |
| 97166 | <1% | 674 | $41K | |
| 77065 | Tomosynthesis, mammo | <1% | 659 | $40K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,845 | $39K |
| 85730 | <1% | 13,436 | $38K | |
| J3490 | Unclassified drugs | <1% | 3,433 | $38K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 232 | $37K |
| 85610 | <1% | 14,390 | $37K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,297 | $36K |
| 86803 | <1% | 5,766 | $34K | |
| 72110 | <1% | 908 | $34K | |
| 87040 | <1% | 3,342 | $34K | |
| 97010 | <1% | 11,458 | $34K | |
| 88342 | <1% | 1,276 | $33K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 9,323 | $33K |
| 80061 | Lipid panel | <1% | 4,614 | $32K |
| 81001 | <1% | 18,886 | $31K | |
| 74018 | <1% | 1,607 | $31K | |
| 81003 | <1% | 14,985 | $27K | |
| 73110 | <1% | 1,331 | $27K | |
| 82077 | <1% | 4,469 | $27K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,560 | $26K |
| 87400 | <1% | 2,870 | $24K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 332 | $24K |
| 86900 | <1% | 5,017 | $24K | |
| 76818 | <1% | 162 | $23K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 1,425 | $23K |
| 84702 | <1% | 3,545 | $23K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 497 | $22K |
| OP278 | <1% | 57 | $22K | |
| 76857 | <1% | 595 | $22K | |
| 82550 | <1% | 5,701 | $21K | |
| 86850 | <1% | 3,129 | $21K | |
| 73502 | <1% | 1,177 | $21K | |
| 72100 | <1% | 979 | $20K | |
| 88304 | <1% | 1,462 | $19K | |
| 93798 | <1% | 588 | $18K | |
| 85027 | <1% | 4,810 | $18K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,697 | $18K |
| G0330 | Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room | <1% | 14 | $17K |
| 84100 | <1% | 7,538 | $17K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,694 | $17K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,305 | $17K |
| 73080 | <1% | 829 | $16K | |
| 86901 | <1% | 3,372 | $16K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,330 | $16K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,151 | $16K |
| 62323 | <1% | 12 | $15K | |
| 97016 | <1% | 2,603 | $15K | |
| 72131 | <1% | 270 | $15K | |
| 82553 | <1% | 2,292 | $15K | |
| 90715 | <1% | 1,410 | $14K | |
| 97597 | <1% | 141 | $14K | |
| 87186 | <1% | 2,645 | $13K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,896 | $13K |
| 87340 | <1% | 4,368 | $13K | |
| 80306 | <1% | 1,229 | $12K | |
| 12011 | <1% | 443 | $12K | |
| J2704 | Injection, propofol, 10 mg | <1% | 9,379 | $12K |
| 76870 | <1% | 242 | $12K | |
| 94727 | <1% | 340 | $12K | |
| 80320 | <1% | 1,544 | $11K | |
| 93356 | <1% | 907 | $10K | |
| 97163 | <1% | 186 | $10K | |
| 12001 | <1% | 387 | $10K | |
| 0004A | <1% | 362 | $10K | |
| 73562 | <1% | 316 | $10K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 14,358 | $9K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,078 | $9K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 429 | $9K |
| 84145 | <1% | 1,607 | $8K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,908 | $8K |
| 87507 | <1% | 143 | $8K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 14,071 | $7K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 5,889 | $7K |
| 82607 | <1% | 1,734 | $7K | |
| 92610 | <1% | 474 | $7K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 4,546 | $7K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 3,941 | $7K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 13 | $6K |
| 94729 | <1% | 148 | $6K | |
| 82150 | <1% | 1,514 | $6K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,879 | $6K |
| 73590 | <1% | 426 | $6K | |
| 73090 | <1% | 281 | $5K | |
| 82728 | <1% | 1,195 | $5K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,352 | $5K |
| 74241 | <1% | 97 | $5K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,213 | $5K |
| 85379 | <1% | 2,427 | $5K | |
| 92508 | Group treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 49 | $5K |
| 84439 | <1% | 1,101 | $5K | |
| 71101 | <1% | 282 | $5K | |
| 36430 | <1% | 135 | $5K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 3,450 | $5K |
| 82746 | <1% | 1,482 | $4K | |
| 86141 | <1% | 1,007 | $4K | |
| 93880 | <1% | 67 | $4K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,725 | $4K |
| 80143 | <1% | 750 | $4K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 343 | $4K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,872 | $4K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 7,780 | $4K |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 1,293 | $4K |
| 87077 | <1% | 1,016 | $4K | |
| 87070 | <1% | 623 | $4K | |
| 74178 | <1% | 14 | $4K | |
| 80179 | <1% | 676 | $4K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 314 | $4K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 12 | $4K |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 2,027 | $3K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,037 | $3K |
| 0071A | <1% | 89 | $3K | |
| 83550 | <1% | 1,155 | $3K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,070 | $3K |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 767 | $3K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 85 | $3K |
| 0072A | <1% | 71 | $2K | |
| 74019 | <1% | 98 | $2K | |
| 97035 | <1% | 162 | $2K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,652 | $2K |
| 70498 | <1% | 27 | $2K | |
| C1769 | Guide wire | <1% | 461 | $2K |
| 96368 | <1% | 99 | $2K | |
| 82043 | <1% | 864 | $2K | |
| 86922 | <1% | 268 | $2K | |
| 85651 | <1% | 1,428 | $2K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 23 | $2K |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 345 | $2K |
| 80076 | <1% | 497 | $2K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 593 | $2K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 209 | $2K |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 20 | $2K |
| 87088 | <1% | 1,307 | $2K | |
| 83540 | <1% | 438 | $2K | |
| J1741 | Injection, ibuprofen, 100 mg | <1% | 192 | $2K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 27 | $2K |
| 82570 | <1% | 921 | $2K | |
| 90846 | Family psychotherapy without the patient present, 50 minutes | <1% | 16 | $2K |
| 92611 | <1% | 19 | $1K | |
| 29125 | <1% | 97 | $1K | |
| 12002 | <1% | 37 | $1K | |
| 70496 | <1% | 29 | $1K | |
| 0064A | <1% | 47 | $1K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 47 | $1K |
| 92522 | <1% | 15 | $1K | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 990 | $1K |
| 70491 | <1% | 26 | $1K | |
| 10060 | <1% | 25 | $1K | |
| 82803 | <1% | 120 | $1K | |
| 51701 | <1% | 68 | $1K | |
| 72052 | <1% | 24 | $998.24 | |
| 85378 | <1% | 285 | $967.66 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 509 | $852.50 |
| 94664 | <1% | 430 | $837.21 | |
| 92526 | <1% | 18 | $827.07 | |
| 83721 | <1% | 115 | $808.31 | |
| 36600 | <1% | 87 | $794.62 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 389 | $756.89 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 1,026 | $751.68 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 696 | $669.51 |
| OP637 | <1% | 3,711 | $651.27 | |
| 86885 | <1% | 187 | $634.49 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 122 | $631.98 |
| 88311 | <1% | 185 | $624.73 | |
| 15853 | <1% | 16 | $622.86 | |
| 0124A | <1% | 25 | $586.15 | |
| 84153 | <1% | 54 | $504.95 | |
| 84550 | <1% | 294 | $458.74 | |
| 73523 | <1% | 15 | $444.61 | |
| OP940 | <1% | 164 | $433.18 | |
| 82977 | <1% | 109 | $425.39 | |
| 73060 | <1% | 25 | $380.00 | |
| 72040 | <1% | 12 | $376.81 | |
| 86592 | <1% | 210 | $372.59 | |
| 74230 | <1% | 19 | $366.41 | |
| 82248 | <1% | 137 | $341.54 | |
| J1836 | Injection, metronidazole, 10 mg | <1% | 184 | $303.78 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,122 | $295.21 |
| 72072 | <1% | 17 | $277.90 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 29 | $245.82 |
| 72170 | <1% | 30 | $202.95 | |
| 87205 | <1% | 85 | $186.90 | |
| 87185 | <1% | 51 | $184.08 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 206 | $183.08 |
| 88313 | <1% | 12 | $176.50 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 29 | $163.32 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 26 | $143.15 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 40 | $140.78 |
| 81025 | <1% | 37 | $137.22 | |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 38 | $135.78 |
| 80329 | <1% | 12 | $134.46 | |
| 86140 | <1% | 111 | $119.91 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 25 | $118.20 |
| 84156 | <1% | 127 | $117.92 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 204 | $106.23 |
| 85384 | <1% | 18 | $105.60 | |
| 84154 | <1% | 14 | $105.21 | |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 59 | $104.63 |
| 90714 | <1% | 25 | $98.05 | |
| 99201 | <1% | 18 | $97.69 | |
| 82272 | <1% | 49 | $96.39 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 103 | $95.95 |
| 88300 | <1% | 12 | $91.64 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 25 | $89.46 |
| A9270 | Non-covered item or service | <1% | 20 | $86.27 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 216 | $86.06 |
| 94760 | <1% | 68 | $84.93 | |
| 87449 | <1% | 25 | $79.13 | |
| 83615 | <1% | 32 | $69.99 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 67 | $65.51 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | <1% | 40 | $56.79 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 544 | $39.00 |
| 82009 | <1% | 59 | $37.00 | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 18 | $34.23 |
| 90686 | <1% | 25 | $32.57 | |
| J0456 | Injection, azithromycin, 500 mg | <1% | 63 | $32.42 |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | <1% | 45 | $32.12 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 464 | $29.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 35 | $27.26 |
| J3590 | Unclassified biologics | <1% | 123 | $25.90 |
| 87075 | <1% | 16 | $22.66 | |
| 84300 | <1% | 13 | $22.59 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 48 | $20.89 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 19 | $18.92 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 63 | $18.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 167 | $16.00 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 55 | $15.06 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 148 | $14.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | <1% | 118 | $12.00 |
| G8982 | Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 129 | $11.00 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 55 | $9.00 |
| G8981 | Changing & maintaining body position functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 103 | $9.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 13 | $8.83 |
| 83718 | <1% | 81 | $8.00 | |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | <1% | 18 | $7.47 |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 35 | $7.00 |
| 91300 | <1% | 4,633 | $7.00 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 17 | $5.72 |
| C1729 | Catheter, drainage | <1% | 24 | $4.00 |
| Q0247 | Injection, sotrovimab, 500 mg | <1% | 16 | $1.00 |
| 91312 | 0% | 25 | $0.00 | |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 19 | $0.00 |
| 91301 | 0% | 18 | $0.00 | |
| 91306 | 0% | 44 | $0.00 | |
| 91307 | 0% | 144 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSAWCZUK, IHOR (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| HMH Hospitals Corporation | Hackensack, NJ | $333.03M |
| HMH Hospitals Corporation | Perth Amboy, NJ | $65.37M |
| HMH Hospitals Corporation | Brick, NJ | $49.91M |
| HMH Hospitals Corporation | Holmdel, NJ | $29.33M |
| HMH Hospitals Corporation | Red Bank, NJ | $26.39M |
| HMH Hospitals Corporation | Old Bridge, NJ | $18.66M |
| HMH Hospitals Corporation | Brick, NJ | $575K |
| Hackensack Specialty Care Associates, PC | Hackensack, NJ | $141K |
| Humc Medical Observation | Hackensack, NJ | $14K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.